Corient Private Wealth
TVTX icon

Corient Private Wealth’s Travere Therapeutics TVTX Stock Holding History

Corient Private Wealth’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Buy
48,125
+648
+1% +$28.7K ﹤0.01% 1183
2026
Q1 		$1.41M Buy
+47,477
New +$1.42M ﹤0.01% 1450

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's TVTX Position: Q2 2026 in Review

Corient Private Wealth increased its Travere Therapeutics (TVTX) stake by 1.4% in Q2 2026, buying an estimated $28.7K and bringing the position to 48,125 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

Corient Private Wealth first reported a position in TVTX in Q1 2026 and has held it in 2 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Corient Private Wealth held 48,125 shares of Travere Therapeutics worth $2.73M as of Q2 2026.
  • Corient Private Wealth bought 648 Travere Therapeutics shares in Q2 2026, an estimated $28.7K.
  • Travere Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1183 holding.
  • Corient Private Wealth first reported a position in Travere Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.